156 related articles for article (PubMed ID: 20933118)
1. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century.
Spitz IM
Contraception; 2010 Nov; 82(5):442-52. PubMed ID: 20933118
[TBL] [Abstract][Full Text] [Related]
2. Current medical abortion care.
Creinin MD
Curr Womens Health Rep; 2003 Dec; 3(6):461-9. PubMed ID: 14613667
[TBL] [Abstract][Full Text] [Related]
3. Antiprogestins: mechanism of action and contraceptive potential.
Spitz IM; Croxatto HB; Robbins A
Annu Rev Pharmacol Toxicol; 1996; 36():47-81. PubMed ID: 8725382
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of progesterone receptor modulators and their effect on the endometrium.
Spitz IM
Curr Opin Obstet Gynecol; 2009 Aug; 21(4):318-24. PubMed ID: 19602929
[TBL] [Abstract][Full Text] [Related]
5. The possible use of antiprogestins for contraception.
Bygdeman M; Danielsson KG; Swahn ML
Acta Obstet Gynecol Scand Suppl; 1997; 164():75-7. PubMed ID: 9225644
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception.
Gemzell-Danielsson K; Marions L
Hum Reprod Update; 2004; 10(4):341-8. PubMed ID: 15192056
[TBL] [Abstract][Full Text] [Related]
7. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
Honkanen H; Piaggio G; Hertzen H; Bártfai G; Erdenetungalag R; Gemzell-Danielsson K; Gopalan S; Horga M; Jerve F; Mittal S; Thi Nhu Ngoc N; Peregoudov A; Prasad RN; Pretnar-Darovec A; Shah RS; Song S; Tang OS; Wu SC;
BJOG; 2004 Jul; 111(7):715-25. PubMed ID: 15198763
[TBL] [Abstract][Full Text] [Related]
8. Early pregnancy termination with mifepristone and misoprostol in the United States.
Spitz IM; Bardin CW; Benton L; Robbins A
N Engl J Med; 1998 Apr; 338(18):1241-7. PubMed ID: 9562577
[TBL] [Abstract][Full Text] [Related]
9. Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties.
Sun Y; Fang M; Davies H; Hu Z
Gynecol Endocrinol; 2014 Mar; 30(3):169-73. PubMed ID: 24205903
[TBL] [Abstract][Full Text] [Related]
10. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol.
Guest J; Chien PF; Thomson MA; Kosseim ML
BJOG; 2007 Feb; 114(2):207-15. PubMed ID: 17305893
[TBL] [Abstract][Full Text] [Related]
11. Use of mifepristone and sublingual misoprostol for early medical abortion.
Lin M; Li YT; Chen FM; Wu SF; Tsai CW; Chen TH; Kuo TC
Taiwan J Obstet Gynecol; 2006 Dec; 45(4):321-4. PubMed ID: 17175490
[TBL] [Abstract][Full Text] [Related]
12. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial.
von Hertzen H; Piaggio G; Wojdyla D; Marions L; My Huong NT; Tang OS; Fang AH; Wu SC; Kalmar L; Mittal S; Erdenetungalag R; Horga M; Pretnar-Darovec A; Kapamadzija A; Dickson K; Anh ND; Tai NV; Tuyet HT; Peregoudov A;
BJOG; 2009 Feb; 116(3):381-9. PubMed ID: 19187370
[TBL] [Abstract][Full Text] [Related]
13. The potential of mifepristone (RU-486) as an emergency contraceptive drug.
Sarkar NN
Acta Obstet Gynecol Scand; 2005 Apr; 84(4):309-16. PubMed ID: 15762958
[TBL] [Abstract][Full Text] [Related]
14. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days.
Brown A; Cheng L; Lin S; Baird DT
J Clin Endocrinol Metab; 2002 Jan; 87(1):63-70. PubMed ID: 11788624
[TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation.
Hamoda H; Ashok PW; Flett GM; Templeton A
BJOG; 2005 Aug; 112(8):1102-8. PubMed ID: 16045525
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion.
Liao AH; Han XJ; Wu SY; Xiao DZh; Xiong CL; Wu XR
Eur J Obstet Gynecol Reprod Biol; 2004 Oct; 116(2):211-6. PubMed ID: 15358467
[TBL] [Abstract][Full Text] [Related]
17. The use of progesterone antagonists and progesterone receptor modulators in contraception.
Spitz IM; Van Look PF; Coelingh Bennink HJ
Steroids; 2000; 65(10-11):817-23. PubMed ID: 11108893
[TBL] [Abstract][Full Text] [Related]
18. Progesterone antagonists and progesterone receptor modulators: an overview.
Spitz IM
Steroids; 2003 Nov; 68(10-13):981-93. PubMed ID: 14667991
[TBL] [Abstract][Full Text] [Related]
19. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial.
Shannon C; Wiebe E; Jacot F; Guilbert E; Dunn S; Sheldon WR; Winikoff B
BJOG; 2006 Jun; 113(6):621-8. PubMed ID: 16709204
[TBL] [Abstract][Full Text] [Related]
20. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception.
Glasier A; Thong KJ; Dewar M; Mackie M; Baird DT
N Engl J Med; 1992 Oct; 327(15):1041-4. PubMed ID: 1522839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
